Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
- 16 October 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 497, 100-111
- https://doi.org/10.1016/j.canlet.2020.10.016
Abstract
No abstract availableKeywords
Funding Information
- St George Cancer Care Centre Research Trust Fund
- Prostate and Breast Cancer Foundation
- UNSW Sydney and China Scholarship Council
This publication has 92 references indexed in Scilit:
- Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling CohortAnnals of Surgical Oncology, 2013
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancerJCI Insight, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studiesDrug Resistance Updates, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediateNucleic Acids Research, 2010
- Triple-negative breast cancer—current status and future directionsAnnals of Oncology, 2009
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancerAnnals of Oncology, 2009
- Carcinoma-Associated Fibroblast–Like Differentiation of Human Mesenchymal Stem CellsCancer Research, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008